

Children's Mercy Kansas City

SHARE @ Children's Mercy

Manuscripts, Articles, Book Chapters and Other Papers

9-1-2016

Pediatric Statin Administration: Navigating a Frontier with Limited Data.

Jonathan B. Wagner
Children's Mercy Hospital

Susan M. Abdel-Rahman
Children's Mercy Hospital

Follow this and additional works at: <https://scholarlyexchange.childrensmc.org/papers>



Part of the [Cardiology Commons](#), [Cardiovascular Diseases Commons](#), [Medical Genetics Commons](#), [Medical Pharmacology Commons](#), [Pediatrics Commons](#), and the [Pharmaceutical Preparations Commons](#)

Recommended Citation

Wagner J, Abdel-Rahman SM. Pediatric Statin Administration: Navigating a Frontier with Limited Data. *J Pediatr Pharmacol Ther.* 2016;21(5):380-403. doi:10.5863/1551-6776-21.5.380

This Article is brought to you for free and open access by SHARE @ Children's Mercy. It has been accepted for inclusion in Manuscripts, Articles, Book Chapters and Other Papers by an authorized administrator of SHARE @ Children's Mercy. For more information, please contact hlsteel@cmh.edu.

Pediatric Statin Administration: Navigating a Frontier with Limited Data

Jonathan Wagner, DO¹⁻³ and Susan M. Abdel-Rahman, PharmD^{2,3}

¹Ward Family Heart Center and ²Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children's Mercy Hospital, Kansas City, Missouri; ³Department of Pediatrics, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri

Increasingly, children and adolescents with dyslipidemia qualify for pharmacologic intervention. As they are for adults, 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors (statins) are the mainstay of pediatric dyslipidemia treatment when lifestyle modifications have failed. Despite the overall success of these drugs, the magnitude of variability in dose-exposure-response profiles contributes to adverse events and treatment failure. In children, the cause of treatment failures remains unclear. This review describes the updated guidelines for screening and management of pediatric dyslipidemia and statin disposition pathway to assist the provider in recognizing scenarios where alterations in dosage may be warranted to meet patients' specific needs.

INDEX TERMS atorvastatin, dyslipidemia, fluvastatin, lovastatin, pediatrics, pharmacogenomics, pharmacokinetics, pravastatin, rosuvastatin, simvastatin, statin

J Pediatr Pharmacol Ther 2016;21(5):380-403

INTRODUCTION

Cardiovascular disease remains the number one cause of mortality in the United States.¹ Despite significant advances in medical and surgical management for heart disease and stroke, the burden of cardiovascular disease remains alarming. Coronary artery disease (CAD) alone accounts for 1 of every 7 deaths in the United States.¹ Although CAD has historically been perceived as a disease of middle to late adulthood, data now support onset at a much younger age. Clinically silent precursors to CAD, fatty streaks, have been observed in children as young as 3 years of age with coronary involvement identified at adolescence.² By the time individuals reach their 20s studies suggest that the incidence of coronary atherosclerosis can range from 45% to 75%.^{3,4} Importantly, several studies confirm that the risk factors observed in adults (e.g., elevated low-density lipoprotein [LDL], obesity, hypertension, tobacco exposure, and diabetes) also contribute to atherosclerosis in children.^{5,6} Collectively, these studies have illuminated the

need for preventive cardiovascular services in children and young adults.

Trends in circulating lipid profiles support a role for screening in children as part of preventative care. The prevalence of total plasma cholesterol (TC) concentrations in excess of 200 mg/dL has risen to 10% in adolescents,^{7,8} a far cry from the estimated 0.2% of the population that can attribute this laboratory finding to familial hypercholesterolemia.^{9,10} This may be explained, in part, by the rate of overweight/obesity in children, which as in adults, can be associated with elevated cholesterol levels.¹¹ Importantly, most adolescents with elevated TC will continue to have elevated TC into adulthood, and those who are overweight have a 2-fold higher relative risk of CAD mortality, independent of adult weight.^{12,13} When pediatric weight and lipid profiles are considered together, the prevalence of symptomatic CAD in young to middle-aged adults is expected to increase by 5% to 16% over the next 2 decades.¹⁴ This will likely contribute to an additional 100,000 cases of early coronary heart disease that are specifically due to childhood obesity.

SCREENING AND MANAGEMENT GUIDELINES

Since the last comprehensive review of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) by Eiland et al,¹⁵ the pediatric screening and management guidelines have changed, prompting this update for pediatric providers who make recommendations related to prescribing statins.

In 1992, the National Cholesterol Education Program (NCEP) began recommending targeted lipid screening in pediatric patients with risk factors for premature atherosclerotic cardiovascular disease.¹⁶ This strategy exposed numerous cases of asymptomatic dyslipidemia that previously would have been neglected for decades. However, additional evidence suggests that simply relying on family history alone will miss at least 30% of pediatric patients with moderate dyslipidemia.¹⁷ These previous NCEP guidelines also focused on LDL screening, essentially ignoring the combined dyslipidemic patterns that are observed in obese pediatric patients (i.e., increased triglycerides, increased LDL, decreased high-density lipoprotein [HDL]).

Realizing that a large proportion of at-risk children would remain unidentified, the National Heart, Lung, and Blood Institute convened an expert panel on Cardiovascular Health and Risk Reduction in Children and Adolescents to update the pediatric preventive cardiovascular guidelines, including modifications to lipid screening and management in childhood and adolescence.¹⁸ The most striking modification in the updated NCEP guidelines resides in the domain on lipid screening where the panel now recommends universal lipid screening for all children between the ages 9 and 11 years and again between 17 and 21 years of age.¹⁸ These age groups were targeted specifically to screen patients prior to and after puberty, when it is observed that TC and LDL can fluctuate with growth and sexual maturity.^{19,20} The updated guidelines also suggest that lipid profiles can be obtained in either the fasting or non-fasting state given the reliability with either method.²¹ This offers the benefit of facilitating screening in busy clinic settings where non-fasting lipid profiles may be easier to obtain.

Treatment guidelines were also clarified in the new guidelines with the goal of minimizing the burden of CAD in young adults. As expected,

Table 1. Treatment Cutpoints for Statin Therapy*

LDL	Presence of Concurrent Factors
≥190 mg/dL	None
160-189 mg/dL	Positive family history of early CVD or 1 high-level RF for early CVD or 2 moderate-level RF for early CVD
130-159 mg/dL	2 high-level RF for early CVD or 1 high-level and 2 moderate-level RF for early CVD

CVD, cardiovascular disease; LDL, low-density lipoprotein; RF, risk factor

* Decisions regarding pharmacologic treatment of dyslipidemia were based on the average results of 2 lipid profiles obtained at least 2 weeks apart but no more than 3 months apart.

diet and exercise are the first steps in which a provider managing children with lipid abnormalities should implement a change. When lifestyle modifications fail to improve lipid profiles over a 6-month period, pharmacologic therapy may be warranted to reverse lipid abnormalities. In children older than 10 years of age, use of pharmacologic management should be based on the average results of 2 lipid profiles obtained at least 2 weeks apart but no more than 3 months apart. The thresholds used to determine when drug therapy should be initiated are mirrored from the 1992 NCEP guidelines outlined in Table 1. The treatment algorithm is based on a combination of LDL level, family history, and/or associated risk factors and/or risk conditions (Table 2).

Contrasted with the adult guidelines which establish a threshold for treatment at ≥190 mg/dL, the implications of expanded drug use in children below this threshold are self-evident. A recent publication quantified this impact in just the adolescent population (17-21 years of age), which effectively spans both pediatric and adult criteria. Applying the pediatric recommendations to this population would result in 6-fold more patients qualifying for statin therapy than would be eligible based on the adult guidelines (2.5% vs. 0.4%, respectively). This equates to approximately 400,000 adolescents.²² This discrepancy illustrates the challenge faced by providers who care for adolescents who are transitioning into adulthood; specifically, whether the risk of exposing significantly more children to chronic lipid-

Table 2. Risk Factor Definitions for Dyslipidemia Guidelines¹⁸

Positive Family History	myocardial infarction, angina, coronary artery bypass graft/stent/angioplasty, sudden cardiac death in parent, grandparent, aunt, uncle at <55 yr for males, < 65yr for females
High level risk	Hypertension that requires drug therapy (BP \geq 99th percentile + 5 mm Hg), current cigarette smoker, BMI at the \geq 97th percentile, presence of special high-risk conditions
Moderate level risk	Hypertension that does not require drug therapy, BMI \geq 95th percentile, <97th percentile, HDL cholesterol < 40 mg/dL, presence of moderate risk conditions
Special high-risk conditions	Type 1 or 2 diabetes mellitus, chronic kidney disease/end-stage renal disease/post-transplantation, post-orthotopic heart transplantation, Kawasaki disease with current aneurysms
Special moderate-risk conditions	Kawasaki disease with regressed coronary aneurysms, chronic inflammatory disease (systemic lupus erythematosus, juvenile rheumatoid arthritis), HIV infection, nephritic syndrome

BMI, body mass index; BP, blood pressure; HDL, high-density lipoprotein; HIV, human immunodeficiency virus; RF, risk factor

lowering medications is offset by the anticipated reduction in morbidity and mortality from CAD. The risk of this chronic extrahepatic exposure of statins in the developing child is described briefly in *Distribution* below. Undoubtedly, additional investigations will be needed to clarify future guideline updates and risk of statin exposure in a developing child.

OVERVIEW OF THE STATINS

As shown by the guidelines, HMG-CoA reductase inhibitors are now the mainstay of pharmacologic treatment for dyslipidemia in both adults and children, due to their demonstrated efficacy in the primary and secondary prevention of CAD coupled with a relatively mild side effect profile.^{15,23-28} The first 3 statins approved in the United States (lovastatin in 1987, simvastatin in 1991, and pravastatin in 1991) are fungus-derived (Tables 3-5) semisynthetic agents, whereas the remaining U.S. Food and Drug Administration-approved compounds (fluvastatin in 1993, atorvastatin in 1996, rosuvastatin in 2003, and pitavastatin in 2009) are synthetic agents (Table 6).²⁹

Pharmacology

Statins decrease the hepatic synthesis of cholesterol by blocking the conversion of HMG-CoA to mevalonate, the rate-limiting step in cholesterol synthesis. In response to a subsequent decrease in intracellular sterols, expression of the genes encoding the cell-surface LDL receptor is up-regulated. This, in turn, enhances the hepatic uptake of LDL and reduces the circulating levels of LDL in the serum.³⁰ However, statins appear to possess other effects including a decrease

in inflammatory mediators downstream from HMG-CoA reductase (see *Future Considerations* below).³¹⁻³³ Thus, it remains debated whether the reduction in CAD and plaque formation occurs as a result of the statins' lipid-lowering effects or other anti-inflammatory effects.

Efficacy in Children

Clinical trials of statins in children have included lovastatin, simvastatin, pravastatin, fluvastatin, rosuvastatin, atorvastatin, and pitavastatin and most of the studies focused on lipid-lowering and safety (Tables 3-6). With few exceptions, exposure to the statins conferred no added safety risk compared with placebo. However, the trials described in Tables 3 to 6 ranged from 1 month to 2 years and thus, a paucity of data describing the safety of chronic exposure to statins initiated during childhood exists. Moreover, for nearly all agents, reductions in LDL exceeded 20%, and some agents achieved reductions in excess of 40% to 50%. There also appeared to be some degree of dose dependence in LDL response within this class of drugs. However, in many studies, the variability associated with mean response profiles was exceedingly large, almost equivalent in magnitude to the response itself (Tables 3-6). At present, the cause of this variability remains unknown.

With such a high degree of variability in LDL reduction at a given statin dose and the unknown long-term developmental consequences of regular pediatric statin use, identifying the dose that maximizes efficacy and minimizes the risk of toxicity (i.e., dose optimization) is of great clinical importance for a developing child. Notably, all studies presented used a "one-size-

Table 3. Lovastatin: Summary of Safety and LDL reduction in Pediatric Trials

Reference	Population	Lovastatin Dosing	LDL reduction (%)	Variance (%)	Safety
Clauss et al ²⁴	n = 54; 11-18 yr (females only) FH	20 mg/day × 4 wks 40 mg/day × 20 wks	23 at wk 4 27 at wk 24	SE 3.3 SE 3.4	no difference vs. placebo
Stein et al ³⁵	n = 132 (65 placebo); 13.3 ± 2.5 yr (males only) FH	10 mg/day × 8 wks 20 mg/day × 8 wks 40 mg/day × 8 wks 40 mg/day × 24 wks	17 24 27 25	SE 2 SE 1 SE 2 SE 2	no difference vs. placebo
Lambert et al ³⁶	n = 69; 13.3 ± 2.7 yr (males only) FH	10 mg qd × 8 wks 20 mg/day × 8 wks 30 mg/day × 8 wks 40 mg/day × 24 wks	21 24 27 36	15 - 27 19 - 29 19 - 35 33 - 39	no SAE, increase in CK

CK, creatinine kinase; FH, familial hyperlipidemia; SAE, serious adverse events; SE, standard error

fits-all" dosage scheme, effectively ignoring the contributions of ontogeny and genetic variation in statin disposition that are assuredly present in pediatric patients.

Given that the use of statins will inevitably increase as a result of mandatory lipid screening programs and the observed difficulties with adherence to dietary/behavioral modifications, the pediatric community should proactively pursue a more comprehensive understanding of these agents in children and adolescents before their widespread use. The following section discusses developmental, physicochemical, and pharmacogenetic factors that influence the dose-exposure profile for the statins. Notably, the paucity of data for pediatric statin disposition requires extrapolation from *in vitro* and adult data.

DISPOSITION

Physicochemical Considerations

Despite sharing a common mechanism of action, the statins differ in their physicochemical properties (e.g., octanol-water partition coefficient, pH stability/solubility). These properties are incredibly important to the overall disposition of each agent and explain why the statins should be considered independently when tailoring dosage to individual patient populations. Two statin agents (lovastatin and simvastatin) are formulated as lactone prodrugs which require hydrolysis to become activated inhibitors of HMG-CoA reductase.^{56,57} The remaining statins are administered in their active hydroxy acid forms.^{31,58,59} Consequently, lovastatin and simvastatin are the most lipophilic as delivered

(simvastatin > lovastatin), readily translocating across membranes,^{60,61} whereas pravastatin and rosuvastatin are the most hydrophilic agents, requiring transporter-mediated disposition.^{58,60,61}

Another unique element of the statins lies with the pH-dependent chemical interconversion that can occur at any step in the disposition pathway and heavily influences the amount of active drug available at the target. For instance, formation of the inactive 3- α -hydroxy-pravastatin acid and lactone isomers in the acidic environment of the stomach prior to absorption can disrupt the amount of pravastatin acid delivered to the drug target (i.e., the liver).^{62,63} Not surprisingly, isomer formation influences the pharmacodynamic effects of these drugs and is highly variable among healthy human subjects.^{63,64} Although these data require replication in a larger cohort before changes can be made to the drug label, the extent of chemical interconversion should be taken into consideration in populations where statin response is highly variable.

Absorption

All statins are administered orally, thus, the extent of their systemic availability is determined by the aforementioned physicochemical properties of the drug, the physicochemical milieu of the patient's gastrointestinal environment, and the functional status of their intestinal transporters, which can be influenced by ontogeny and genetics.

Pravastatin preferentially undergoes transporter-mediated absorption, conferring a relatively robust absorption rate despite its hydrophilic properties.⁶⁵ *In vitro*, pravastatin appears to be

Table 4. Pravastatin: Summary of Safety and LDL Reduction in Pediatric Trials

Reference	Population	Pravastatin Dosing	% LDL Reduction	% Variance	Safety
Hedman et al ⁴³	n = 20; 4.9-15.6 yr FH	10 mg/day × 8 wk	21	Not reported	No SAE
Hedman et al ⁴⁴	n = 19; 4.4 - 18.9 yr cardiac transplant	10 mg/day × 8 wk	27	SD 27	No SAE, mild increase in CK
Hedman et al ⁴⁵	n = 35; 4.1 - 18.5 yr FH n = 35	10 mg/day Titration by 10 mg at 8, 16, 24, 52, 104 wk per LDL goal	25 at wk 8 27 at wk 16 29 at wk 24 33 at wk 52 32 at wk 104	SD 11 SD 13 SD 13 SD 14 SD 13	No SAE
Hedman et al ⁴⁶	n = 20; 4.9 - 15.6 yr FH	10 mg/day × 8 wk	20 (TT) 23 (TC)	SD 10 SD 12	No SAE
Hedman et al ⁴⁶	n = 12; 4.4 - 18.7 yr cardiac transplant	10 mg/day × 8 wk	34 (TT) 8 (TC)	SD 21 SD 8	No SAE
Knipscheer et al ⁴⁷	n = 72; 8 - 16 yr FH	5 mg/day × 12 wk 10 mg/day × 12 wk 20 mg/day × 12 wk	23 24 33	18-28 19-29 29-37	No difference between groups
Wiegman et al ⁴⁸	n = 214; 13 ± 3 yr FH	20 or 40 mg/day (< 14 vs. ≥ 14yr) × 104 wk	24	SD 17	No difference vs. placebo

CK, creatinine kinase; FH, familial hyperlipidemia; LDL, low-density lipoprotein; SAE, serious adverse events; SD, standard deviation; TC, SLCO1B1 521TC heterozygote genotypes; TT, SLCO1B1 521TT wild-type genotypes.

a substrate for the influx transporters OATP1A2 and OATP2B1. Notably, OATP2B1 uptake appears to be pH-sensitive, diminishing greatly as the pH increases from 5.0 to 7.4.⁶⁶⁻⁶⁸ This observation suggests that the primary impact of OATP2B1 translocation occurs at the level of the enterocyte, where it is exposed to lower pH values, as opposed to the hepatocyte, where the systemic pH is higher and less uptake is expected. Pravastatin is not a substrate for the efflux transporters MDR1 and BCRP but, *in vitro*, appears to be a substrate for the efflux transporter MRP2, which is located on the apical surface of the enterocyte and liver.⁶⁸⁻⁷¹ *In vivo*, increased expression of MRP2 conferred by a 'gain of function' sequence variation (ABCC2 c.1446C>G), increases presystemic clearance and reduces the bioavailability of pravastatin at the level of the enterocyte.⁷²

Rosuvastatin similarly undergoes transporter-mediated absorption and, although not fully characterized, also appears to be a substrate for

OATP2B1 and BCRP.^{73,74} However, rosuvastatin does not display the same pH sensitivity suggesting that OATP2B1 may be relevant to rosuvastatin disposition at the level of both the intestine and liver.⁷³ *In vivo*, a genetic variation in the gene encoding BCRP (ABCG2 c.421C>A) contributes to an increase in rosuvastatin exposure by way of diminished export back into the intestinal lumen and into the biliary canaliculus.^{75,76}

Fluvastatin, moderately more lipophilic than pravastatin or rosuvastatin, undergoes passive diffusion but *in vitro* is a substrate of OATP2B1.⁷³ Similarly, *in vitro* data reveal that atorvastatin is an OATP2B1 substrate at acidic and neutral pH; however, the high passive diffusion rates that are observed and lack of disruption in absorption by known inhibitors of OATP2B1 suggest that this transporter plays a very minor role in the absorption of atorvastatin.⁷³ Pitavastatin, also moderately lipophilic, undergoes passive diffusion and there is no evidence that transporter-mediated influx significantly influences the

Table 5. Simvastatin Summary of Safety and LDL Reduction in Pediatric Trials

Reference	Population	Simvastatin Dosage	% LDL Reduction	% Variance	Safety
de Jongh et al ³⁷	n = 173; 14.4 ± 2.1 yr FH	10 mg/day × 8 wk 20 mg/day × 8 wk 40 mg/day × 8 wk 40 mg/day × 24 wk	31 at wk 8 35 at wk 16 38 at wk 24 41 at wk 48	SD 11 SD 12 SD 16 SD 39	No SAE, Slight decrease in DHEA-S
Ferreira et al ³⁸	n = 36; 10.3 ± 4 yr HC	10 mg mg/day × 4 wk	37	SD 12	No difference vs. placebo
Dirisamer et al ³⁹	n = 20; 13 ± 2.4 yr FH	5 or 10 mg/day (LDL < 220 vs. ≥ 220) step-wise titration up to 20 mg × 52 wk	25 (5 mg) 30 (10 mg) 36 (20 mg)	Not reported	No differences between groups
de Jongh et al ⁴⁰	n = 50; 14.2 ± 3.1 yr FH	10 mg/day × 8 wk 20 mg/day × 8 wk 40 mg/day × 12 wk	40	19%	No differences vs. placebo
Stefanutti et al ⁴¹	n = 16; 4 - 12 yr FH	10 mg/day × 52 wk	29	Not reported	No difference vs. placebo
Garcia-de-la-Puente et al ⁴²	n = 25; 4 - 17 yr renal disease	5 or 10 mg/day (≤30 vs. >30 kg) × 4 wk 10 mg or 20 mg titration (at wk 4) × 8 wk	34	Not reported	No difference vs. placebo

DHEA-S, dehydroepiandrosterone-sulfate; FH, familial hyperlipidemia; HC, hypercholesterolemia; LDL, low-density lipoprotein; SAE, serious adverse events; SD, standard deviation.

disposition of this drug. However, pitavastatin absorption can be attenuated presystemically by P-glycoprotein (P-gp).^{77,78} Finally, there is no reported transporter-mediated absorption influencing the simvastatin or lovastatin lactones.

Another factor for consideration with respect to the absorption of statins is the impact of coadministered meals. Regardless of whether the drug is delivered by solution or capsule, concurrent administration of fluvastatin with food markedly reduces exposure and delays absorption (area under the curve [AUC], -17% to -24%; C_{max} , -60% to -73%; T_{max} , +56%).⁷⁹ This was also observed with pravastatin (AUC, -30%; C_{max} , -49%; T_{max} , +50%)⁸⁰ and rosuvastatin (AUC, -93%; C_{max} , -93%; T_{max} , +10%).⁸¹ However, meals markedly slow the rate of absorption for atorvastatin (T_{max} , +124%) and pitavastatin (T_{max} , +143%). In fed states, atorvastatin C_{max} (-48%) and pitavastatin C_{max} (-55%) are reduced, although the impact on the extent of exposure for atorvastatin (AUC, -13%) and pitavastatin (AUC, -15%) is less pronounced.^{82,83} In contrast, lovastatin concentrations drop when administered under fasting

conditions (~33%),⁸⁴ whereas simvastatin can be taken without regard to meals.⁸⁵

A final observation is the differential effect of morning versus evening dosage for the statin agents. When pravastatin is given in the evening, the C_{max} and AUC are reduced by approximately 60% compared with those for morning dosage.⁸⁶ Similarly, the C_{max} and AUC of atorvastatin are reduced by roughly 30% when administered in the evening.⁸⁷ Fluvastatin concentrations are reported to be higher following evening dosage,⁸⁸ while no significant differences were observed for rosuvastatin.⁸⁹ These differences in drug exposure relative to the timing of dosage could be secondary to physiologic patterns of gastric emptying. Circadian changes in drug absorption have been observed in response to increased gastric emptying times in the evening.⁹⁰ Additionally, the diurnal pattern of cholesterol biosynthesis (peak, 12:00 midnight to 4:00 AM) in relation to an evening dose could increase amount of statin used by the hepatocyte and thereby affect the plasma exposure of a statin.^{91,92} Whether these differences definitely arise as a result of changes

Table 6. Synthetic Statins: Summary of Safety and LDL Reduction in Pediatric Trials

Agent (reference)	Population	Dosage	% LDL Reduction	% Variance	Safety
Fluvastatin (van der Graaf et al ⁴⁹)	n = 84; 12.6 ± 2.1 yr FH	20 mg/day for 6 wk Titration to 40- or 80-mg intervals per LDL × 96 wk	34	29 - 39	N/A, no placebo arm
Atorvastatin (McCrinkle et al ⁵⁰)	n = 187; 14.1 ± 2.0 yr FH or severe HC	10 mg/day titration to 20 mg at wk 4 based on LDL continuing over 26 wk	40	SE 1	No difference vs. placebo
Atorvastatin (Gandelman et al ⁵¹)	n = 39; 6 to <18 yr FH	5 or 10 mg/day × 8 wk (< 10 vs ≥ 10yr) Titration per LDL at wk 4	37 (5 mg) 43 (5 mg to 10 mg) 38 (10 mg) 41 (10 mg to 20 mg)	SD 11 SD 6 SD 8 SD 12	No difference between groups
Atorvastatin (Argent et al ⁵²)	n = 18; 13 ± 4 renal transplant	5 or 10 mg/day (< 40 kg vs. ≥ 40 kg) × 36 wk	57	SD 7	No difference vs. untreated
Rosuvastatin (Avis et al ⁵³)	n = 176; 13.8 ± 1.7 FH	5, 10, 20 mg/day titration at wk 12 per LDL × 40 wk	38 45 50	SD 13 SD 17 SD 14	No difference vs. placebo
Rosuvastatin (Marais et al ⁵⁴)	n = 44; 8 - 63 yr hoFH	20 mg/day × 6 wk 40 mg/day × 6 wk 80 mg/day × 6 wk	19 23 21.4	SD 16 SD 15 SD 21	No SAE
Pitavastatin (Braamskamp et al ⁵⁵)	n = 106; 6 - 17 yr FH	1 mg/day × 12 wk 2 mg/day × 12wk 4 mg/day × 12wk	23.5 30.1 39.3	SE 2.1 SE 2.1 SE 2.2	DHEA-S significantly decreased (4 mg group)

DHEA-S, dehydroepiandrosterone-sulfate; FH, familial hyperlipidemia; HC, hypercholesterolemia; hoFH, homozygous familial hyperlipidemia; LDL, low-density lipoprotein; SAE, serious adverse events; SD, standard deviation; SE, standard error.

in absorption, distribution or elimination or intrinsic cholesterol production patterns remains unclear; however the observation that these patterns do not appreciably alter lipid-lowering properties of the affected statins limits the clinical relevance of these findings.

Concurrent with and subsequent to oral absorption, the statins (with the exception of pitavastatin) are subject to extensive first-pass extraction, effectively reducing their bioavailability.^{29,59,93-96} Because drug-metabolizing enzymes mediate statin metabolism, these reactions are reviewed in *Metabolism* below. However, we point out here that when first-pass occurs at the level of the intestinal enterocyte, the absolute bioavailability of these agents is reduced, influencing both efficacy and toxicity. In contrast, when hepatocytes are the principal mediators of first pass, a more favorable scenario is set where concentrations at the target organ (i.e., the liver)

increase while peripheral exposure decreases, thereby leading to enhanced efficacy and fewer side effects (e.g., myalgias).⁹⁷

Distribution

Hepatic uptake for the highly lipophilic statin lactones occurs by passive diffusion,⁶⁰ but for most of the statins, it is facilitated by transporter-mediated processes. OATP1B1, encoded by the solute-carrier organic anion transporter gene *SLCO1B1*, is the principle transporting protein into the hepatocyte for most statins and has been reviewed extensively.^{60,98-100} Among the transporters with a minor role in statin disposition, pitavastatin, rosuvastatin, and fluvastatin are substrates for OATP1B3 (*SLCO1B3*),^{60,101,102} rosuvastatin and fluvastatin appear to be substrates for OATP2B1 (*SLCO2B1*),^{73,103,104} and rosuvastatin also appears to be a substrate for the sodium-dependent cotransporting polypeptide

(NTCP) which may account for as much as 35% of its hepatic uptake.¹⁰³ Fluvastatin also appears to enter the hepatocyte by passive diffusion.¹⁰⁵⁻¹⁰⁷ As above, cellular uptake of the simvastatin and lovastatin lactones relies primarily on passive diffusion; however, simvastatin and lovastatin acid are substrates of OATP1B1 *in vitro* and *in vivo*.^{108,109} Notably, the simvastatin and lovastatin lactones appear to inhibit OATP1B1-mediated transport.^{110,111}

The clinical relevance of OATP-mediated statin disposition has been demonstrated in a number of drug-drug interaction studies. A 7-fold increase in the AUCs of atorvastatin acid and 2-hydroxy atorvastatin acid and a 3-fold increase in AUC of 4-hydroxy atorvastatin acid were observed when this statin was coadministered with rifampin (a known inhibitor of OATP1B1 and OATP1B3).¹¹²⁻¹¹⁴ In the presence of cyclosporine (a potent inhibitor of OATP1B1 and CYP3A4) atorvastatin AUCs were 6- to 15-fold increased,¹¹⁵⁻¹¹⁷ fluvastatin AUC was 3-fold increased,¹¹⁸ lovastatin AUC was 20-fold increased,¹¹⁹ pitavastatin AUC was 5-fold increased,⁹⁹ pravastatin AUC was 5- to 10-fold increased,^{44,119,120} rosuvastatin AUC was 7-fold increased,¹²¹ and simvastatin AUC was 3- to 8-fold increased.^{122,123} Certainly, CYP3A4 inhibition from cyclosporine can contribute to the overall increases observed in statin exposure; however, this can be concluded to play a minor role given that rosuvastatin, pravastatin, and pitavastatin are not significantly metabolized by CYP3A4.¹²⁴⁻¹²⁸ In fact, pravastatin, the most hydrophilic compound, had a 10-fold increase in AUC when administered to children and adolescents who were taking triple immunosuppressive therapy containing cyclosporine and no other CYP substrates.⁴⁴ Gemfibrozil, also an inhibitor of OATP1B1 and CYP2C8, produced a 2-fold increase in AUCs of atorvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin.^{99,129-133}

Cumulatively, the data from the above-described studies provide compelling evidence that OATP1B1 is a critically important determinant of drug disposition for most of the statins. Consequently, functional polymorphisms in the *SLCO* gene families are also expected to influence statin disposition and, thus, have been the subject of considerable interest.^{99,134} Much of this work stems from a study of pravastatin pharmacokinetics, where extreme outliers were

attributed to 2 single-nucleotide variants in *SLCO1B1*.¹³⁵ These mutations were observed in the promoter region (-11187G>A) and in exon 5 (c.521T>C) and were associated with a 50% reduction in non-renal clearance.¹³⁶ This finding was independently confirmed in heterozygous carriers of *SLCO1B1**15 (containing the 388A>G and 521T>C variants) who demonstrated mean pravastatin exposures (AUC₀₋₁₂) that were 93% higher and heterozygous carriers of the *17 haplotype (containing the -11187G>A, 388A>G, and 521T>C variants) who had exposures that were 130% higher than non-carriers.¹³⁷

Ultimately, the functional consequence of *SLCO1B1* sequence variations on statin exposure are reflected by the dependence of the individual statin on OATP1B1 for cellular uptake. Heterozygosity for *SLCO1B1**5 and *15 haplotypes is associated with a 3-fold, 2.5-fold, and 2-fold increase in exposure for simvastatin acid, atorvastatin and pravastatin, respectively, with very little effect on fluvastatin.⁹⁹ *SLCO1B1* genotype also influences the effect of rifampin on atorvastatin exposure wherein a 9-fold increase in AUC is observed in patients with a fully functional 521TT genotype versus a 5-fold increase in AUC observed for the 521CC genotype.¹³⁸ We would be remiss not to allude to the *in vitro* data which suggest that the C800T variant of NTCP may confer enhanced uptake of rosuvastatin, but there are no clinical data to support a role for this mutation *in vivo*.¹⁰³

These studies underscore the critical role of OATP1B1 in statin disposition. By extension, this has important implications for drug safety, where an increase in systemic exposure mediated by reduced OATP1B1 activity can increase the risk of myopathy in statin-treated patients. The Statin Response Examined by Genetic Haplotype Markers (STRENGTH) trial demonstrated this with the observation that patients who were heterozygous for a non-coding sequence variation in linkage disequilibrium with c.521T>C experienced a 4.5-fold increase in risk of myopathy. Patients who were homozygous for this mutation experienced a 16.9 increase in risk of myopathy.¹³⁹

All statins, except for pravastatin, are extensively protein bound.^{56,57,65,95,96,125,140,141} Therefore, the circulating concentration of free drug is relatively low for most agents in this class. However, the extent of distribution into peripheral tissues in humans is not well characterized. In theory, the statins with reduced lipid solubility (e.g.,

pravastatin) should demonstrate less extensive tissue distribution, which would ostensibly provide a safer alternative in children, where brain and gonadal tissues are still maturing. *In vitro* and *in vivo* data support this supposition, demonstrating that lower exposures are observed for pravastatin than for lovastatin and simvastatin in the central nervous system,^{142,143} and pravastatin also manifests a lower risk of myopathy than simvastatin and atorvastatin do.¹⁴⁴⁻¹⁴⁹ However, there are contradictory data which suggest that pravastatin can influence gene expression in the central nervous system to the same extent as some of the other statins.¹⁴³ Until the active transporters responsible for tissue distribution of the statins and their ontogeny in children are more fully elucidated, practitioners will need to rely on the adverse event profiles reported from clinical studies.

Metabolism

Although *in vitro* reaction phenotyping studies suggest that cytochromes P450 (CYP) 2C8, 2C9, 2C19, 2D6, 3A4, and 3A5 are all capable of metabolizing the statins, current data suggest that CYP3A4 is a major contributor to simvastatin, lovastatin, and atorvastatin metabolism.^{95,150-152} In the presence of the CYP3A4/5 inhibitor troleanomycin, simvastatin acid metabolism is decreased by 90%.¹⁵⁰ When administered concurrently with the CYP3A4 inhibitor itraconazole, 15- to 19-fold increases are observed in simvastatin and lovastatin AUCs.^{98,126-128} The impact of itraconazole on the AUC of atorvastatin is more modest (+47%),¹⁵¹ and the coadministration of CYP3A4 inhibitors has no significant effect on clearance of pravastatin, fluvastatin, rosuvastatin, or pitavastatin, consistent with the limited role of CYP3A4 in the metabolism of these compounds.¹⁵³ *In vitro* and *in vivo* data suggest that fluvastatin is a substrate for CYP2C9,¹⁵⁴⁻¹⁵⁶ whereas pravastatin, pitavastatin, and rosuvastatin do not undergo appreciable CYP-mediated metabolism.

Despite the fact that CYP3A4 activity is highly variable, mutations driving this variability have not been fully elucidated.¹⁵⁷ However, a sequence variation in intron 6 of this gene associated with reduced CYP3A4 expression and activity (rs35599367 C>T, designated CYP3A4*22) has also been associated with the need for 0.2- to 0.6-fold lower doses of atorvastatin, lovastatin,

and simvastatin to adequately manage lipid profiles.^{158,159} With fluvastatin, patients homozygous for the *3 allele of CYP2C9 (which confers reduced activity in this enzyme) demonstrate 3-fold lower clearance values of the active fluvastatin enantiomer. Notably, the resultant lipid profiles were not correlated with CYP2C9 genotype.¹⁶⁰ Collectively, these studies support a role for allelic variations in drug-metabolizing enzymes influencing the pharmacokinetics and, in some cases, pharmacodynamics of the statins that rely on these pathways for clearance.

UDP-glucuronosyl transferase (UGT)-catalyzed conjugation is the primary route by which statins and their metabolites are further biotransformed in hepatocytes.^{161,162} The open acids are conjugated by UGT to form an acyl glucuronide that subsequently cyclizes to form a lactone ring (i.e., lactonization). This process results in a loss of pharmacologic activity and is common to all statins present in the open acid form. Notably, carboxyl esterase can reverse the lactonization process thereby regenerating the open acids. Alternatively, the lactones can be directly metabolized by the CYPs in a process that appears to occur more rapidly than is observed for open acids.^{60,163} Although important in the disposition of statins, the overall contribution of UGTs is quantitatively less substantial than that of the CYPs.¹⁶³ As above, pravastatin, rosuvastatin, and pitavastatin do not undergo extensive UGT-mediated conjugation.

Although conjugation plays a more limited role in statin disposition, recent data suggest that allelic variants of UGT may have a modest effect of statin activity. The UGT1A3*2 allele has been associated with increased lactonization activity for atorvastatin.¹⁶⁴ Homozygosity of the UGT1A3*2 allele was accompanied by a 1.7- and 2.7-fold increase in AUC of the parent and 2-hydroxyatorvastatin lactones, respectively, compared to that in patients who are homozygous for UGT1A3*1. Furthermore, this increase in lactone formation correlated with a reduction in the maximal effect of atorvastatin on total and LDL cholesterol-lowering from baseline.¹⁶⁵

Excretion

Biliary excretion of the UGT-conjugated statins occurs through several transporters, including multidrug resistance 1 (MDR1; *ABCB1*), multidrug resistance-associated protein 2 (MRP2;

ABCC2), breast cancer resistance protein (BCRP; ABCG2), and bile salt exporting pump (BSEP; ABCB11). However, the quantitative importance of these efflux transporters in the overall disposition profile of the statins has yet to be fully elucidated. Nonetheless, the consequences of genetic variations in the efflux transporters relevant to the statins have also recently been examined. *In vitro*, there is no consensus regarding MDR1 expression or activity in the common allelic variants of ABCB1 (c.1236C>T, c.2677G>T/A, c.3435C>T).¹⁶⁶ *In vivo*, these allelic variants do not appear to significantly influence the inter-individual variability in fluvastatin, pravastatin, lovastatin, and rosuvastatin pharmacokinetics,¹⁶⁷ but significantly increase the exposure of simvastatin and atorvastatin acid by 60% and 55%, respectively.¹⁶⁸

Conversely, the ABCG2 c.421C>A variant, which has been associated with transport activity *in vitro*,¹⁶⁹ appears to increase the exposure of atorvastatin, fluvastatin, simvastatin lactone, and rosuvastatin by 72%, 72%, 111%, and 144%, respectively, in subjects with the AA genotype compared to those in patients with the wild-type CC genotype.^{75,170} Note that this genotype does not appreciably impact the pharmacokinetics of simvastatin acid or pravastatin.¹⁷⁰ As discussed in *Absorption* above, pravastatin is subject to MRP2-mediated transport *in vitro* at the level of the enterocyte and hepatocyte.⁶⁹⁻⁷¹ *In vivo*, the ABCC2 c.1446C>G variant decreases the exposure of pravastatin (AUC, -68%) compared to wild-type controls secondary to a "gain of function" mutation.⁷² It remains unknown whether this decrease in exposure is due to enhanced pre-systemic and/or hepatic clearance. Conversely, MRP2-deficient rats have significantly diminished biliary clearance of pravastatin,⁷¹ and *in vitro* data suggest that BSEP may be an alternative mechanism by which pravastatin is cleared from the hepatocyte.¹⁷¹

Renal clearance is far less pronounced than biliary excretion. Most of the statin agents have minimal renal clearance (< 10%) after an orally administered dose,^{56,57,59,79,124,172} except for pravastatin in which 20% is renally cleared.⁶² The exposure of pravastatin acid is not impacted by diminished renal function; however, exposure of the 3-alpha-hydroxy-pravastatin metabolite was significantly increased (AUC, +48%) compared to that in subjects with normal renal function.¹⁷³

Halstenson et al¹⁷³ suggest that this increased interconversion occurs secondary to decreased gastric pH, which is a direct result of kidney-related metabolic changes. Hepatic conversion to 3-alpha-5-beta, 6-beta-trihydroxy isomeric metabolite occurs more frequently in severe renal impairment, suggesting that more pravastatin acid is cleared hepatically. Although renal impairment does not appear to alter the exposure of pravastatin acid, the impact of both metabolites on statin disposition and response require further investigation. *In vitro*, pravastatin is a substrate of organic anion transporter 3 (OAT3), a transporter located on basolateral membrane of the proximal tubule, and it is responsible for its uptake in the kidney.^{174,175} *In vitro*, gemfibrozil inhibits pravastatin uptake in OAT3-expressing cells.¹⁷⁶ *In vivo*, coadministration of pravastatin and gemfibrozil lead to an increase in pravastatin exposure (AUC, +202%) and decreased renal clearance (-40%).¹³¹ This 40% reduction in renal clearance does not solely explain the increase in pravastatin exposure, but it could serve as a contribution to pravastatin disposition. Further investigation by Nishizato et al¹³⁶ found that several OAT3 single-nucleotide polymorphisms did not affect pravastatin pharmacokinetics.¹³⁶ However, the single-nucleotide polymorphisms included in this analysis have not been associated with decreased transporter function. Overall, patients with renal impairment do not require dose adjustments, but the impact of renal clearance with pravastatin administration requires further elucidation.

Given the current state of our knowledge of the disposition pathways for the available statins (most of which mature prior to adolescence) and the relative absence of data on the ontogeny of transporter expression which could influence recommendations for statin dosage in children, considerations for the selection of statin agents in the pediatric population will largely reflect the same considerations used with adult patients. To maximize the dose-exposure profile, considerations include whether the patient is receiving gastric acid-modifying therapy and whether greater adherence is anticipated to a regimen that requires medication administration with or without meals. To influence the exposure-response profile, one should consider the genetic constitution of the patient, the concurrent administration of drugs that

Table 7. Statin Studies Under Non-Hyperlipidemic Conditions

Condition	Investigated Mechanism(s)
Autoimmune myocarditis ^{181,182}	Inhibit expression of inflammatory cytokines Reduce infiltration of T cells Improve myocardial repolarization
Cardiac allograft vasculopathy ¹⁸³⁻¹⁹⁰	Improve prognosis post-transplant Reduce expression of cell adhesion molecules Reduce graft rejection Reduce circulating monocytes Improve survival
Cancer ¹⁹¹⁻¹⁹⁵	Stimulate antiproliferation Promote apoptosis Inhibit angiogenesis Inhibit cell migration
Chronic kidney disease ¹⁹⁶⁻¹⁹⁸	Decrease decline in GFR Prevent contrast induced acute kidney injury Decrease risk of stroke
Fracture injuries, bone healing, & osteoporosis ¹⁹⁹⁻²⁰⁴	Promote mesenchymal cell differentiation to osteoblasts Protect osteoblasts from apoptosis Reduce osteoclast activity and bone resorption
HIV ²⁰⁵⁻²¹¹	Slow progression of vascular disease on ART Improve flow-mediated vasodilation Implement immunomodulation Reduce all-cause mortality
Immunomodulation ²¹²⁻²¹⁴	Inhibit interferon production Decrease T cell activation
Infection ²¹⁵⁻²¹⁸	Reduce risk of mortality from bacterial and viral infection
Lupus ²¹⁹⁻²²²	Reduce C-reactive protein Reduce circulating chemokines Improve endothelial function
Polycystic ovary syndrome ²²³⁻²²⁵	Reduce markers of inflammation Reduce androgenic steroid concentrations
Rheumatoid arthritis ²²⁶⁻²³¹	Reduce risk of mortality Reduce joint pain/swelling Reduce markers of inflammation
Rotator cuff injury ^{232,233}	Stimulate migration and adhesion of tenocytes Protect against hyperlipidemia-associated RC injury
Sickle cell disease ^{178,234-236}	Reduce thrombin generation/lower circulating procoagulants Improve endothelial dysfunction

ART, antiretroviral therapy; GFR, glomerular filtration rate; HIV, human immunodeficiency virus; RC, rotator cuff

compete as substrates for transport pathways, and comorbidities that may alter circulating protein stores of the presence of protein-binding displacers in the circulation. Future studies on the pharmacokinetics of statins in the pediatric population, and an expansion of our knowledge on the developmental patterns of transport expression, will permit clinicians to further individualize the selection and dosage of statins in this population.

FUTURE CONSIDERATIONS

Owing to their pleiotropic effects, the statins have been extensively evaluated for non-hyperlipidemic conditions, a few of which are detailed in Table 7, and many of which can impact children. For example, patients with sickle cell disease can develop oxidative stress and chronic inflammation to their distal vasculature as a result of transient vaso-occlusion and subsequent

reperfusion injury.¹⁷⁷ Hoppe et al¹⁷⁸ found that biomarkers of vascular dysfunction, including C-reactive protein and interleukin 6, were decreased in adolescents with sickle cell disease from 50% to 70% after a 3-week trial of low (20 mg) or moderate (40 mg) doses of simvastatin.

Additionally, statins have been used after cardiac transplantation to prevent coronary allograft vasculopathy (CAV). In pediatric cardiac transplantation, the prevalence of CAV has been reported to be as high as 17% in one retrospective analysis.¹⁷⁹ Greater-than-optimal LDL concentrations (>100 mg/dL) post transplantation have been reported in 39% of pediatric patients 1 year after transplantation,¹⁸⁰ which can be secondary to post-transplantation steroid and immunosuppressive therapy. The addition of pravastatin therapy in pediatric cardiac transplant recipients yielded a lower incidence of CAV.¹⁷⁹

Most of the remaining conditions for which statins have been explored exploit the anti-inflammatory and antiproliferative effects of these drugs (Table 7). Thus, it would not be unexpected to see statin coadministration in the presence of infections, fractures, and malignancies in children. However, it should be appreciated that there are an equally large number of publications that refute a role for statins in these same conditions (Table 7). In the absence of sufficient prospective clinical trials to inform the role of these agents for indications other than hyperlipidemia, the practitioner must carefully weigh the risk-benefit ratio of these agents and thoughtfully examine the *in vitro* concentration-effect profiles to inform whether and at what dose these agents should be used in pediatric patients.

CONCLUSIONS

With precursors of CAD appearing in childhood, the establishment of pediatric preventive cardiology services is rapidly emerging. However, the most appropriate management of those children and adolescents, where lifestyle changes fail, remains challenging. Despite the overall success of statins, variability in drug response in the pediatric cohort remains concerning. Although not discussed above, genes involved with drug response may contribute to some of the variability in LDL reduction among children and

adults receiving statin therapy.²³⁷⁻²⁴¹ However, it remains unknown whether a consistent statin concentration (i.e., exposure) at the drug target was achieved in these studies. Therefore, future investigations must be designed to characterize these dose-exposure relationships in the developing child so that exposure can be controlled when attempting to determine response in this population. Once the covariates that influence statin disposition in children are validated, future clinical trials will be better informed to fully characterize the entire dose-exposure-response relationship. With these data, dosage will be optimized to maximize efficacy while minimizing toxicity in the individual pediatric patient. In the interim, understanding the statin disposition pathway will assist pediatric providers who make recommendations related to statin prescribing where alteration of drug delivery and dosage may be appropriately tailored to meet their specific patient needs.

Disclosure The authors declare no conflicts or financial interest in any product or service mentioned in the manuscript, including grants, equipment, medications, employment, gifts, and honoraria.

Abbreviations AUC, area under the curve; BCRP, breast cancer resistance protein; BSEP, bile salt exporting pump; CAD, coronary artery disease; CAV, coronary allograft vasculopathy; C_{max} , maximal concentration; CVD, cardiovascular disease; CYP, cytochrome p450; HDL, high-density lipoprotein; HMG-CoA, 3-hydroxy-3-methylglutaryl-coenzyme A; LDL, low-density lipoprotein; MDR1, multi-drug resistance gene; MRP2, multi-drug resistance-associated protein 2; NCEP, National Cholesterol Education Program; NTCP, sodium-dependent co-transporting polypeptide; OAT, organic anion transporter; OATP, organic anion transporting polypeptide; TC, total cholesterol; T_{max} , time of maximal concentration; UGT, UDP-glucuronosyl transferase

Correspondence Jonathan Wagner, DO, Children's Mercy Hospital and Clinics, 2401 Gillham Road, Kansas City, MO 64108, email: jbwagner@cmh.edu

REFERENCES

1. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. *Circulation*. 2015;131(4):e29-322.

2. Holman RL, Mc GH Jr, Strong JP, Geer JC. The natural history of atherosclerosis: the early aortic lesions as seen in New Orleans in the middle of the of the 20th century. *Am J Pathol*. 1958;34(2):209-235.
3. Enos WF, Holmes RH, Beyer J. Coronary disease among United States soldiers killed in action in Korea: preliminary report. *J Am Med Assoc*. 1953;152(12):1090-1093.
4. McNamara JJ, Molot MA, Stremple JF, Cutting RT. Coronary artery disease in combat casualties in Vietnam. *JAMA*. 1971;216(7):1185-1187.
5. Newman WP, 3rd, Freedman DS, Voors AW, et al. Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis. The Bogalusa Heart Study. *N Engl J Med*. 1986;314(3):138-144.
6. McGill HC Jr, McMahan CA. Determinants of atherosclerosis in the young. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) research group. *Am J Cardiol*. 1998;82(10B):30T-36T.
7. Hickman TB, Briefel RR, Carroll MD, et al. Distributions and trends of serum lipid levels among United States children and adolescents ages 4-19 years: data from the Third National Health and Nutrition Examination Survey. *Prev Med*. 1998;27(6):879-890.
8. Kit BK, Carroll MD, Lacher DA, Sorlie PD, DeJesus JM, Ogden C. Trends in serum lipids among US youths aged 6 to 19 years, 1988-2010. *JAMA*. 2012;308(6):591-600.
9. Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG. Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. *J Clin Endocrinol Metab*. 2012;97(11):3956-3964.
10. Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. *J Clin Lipidol*. 2011;5(3):133-140.
11. Ogden CL, Carroll MD, Flegal KM. High body mass index for age among US children and adolescents, 2003-2006. *JAMA*. 2008;299(20):2401-2405.
12. Lauer RM, Clarke WR. Use of cholesterol measurements in childhood for the prediction of adult hypercholesterolemia. The Muscatine study. *JAMA*. 1990;264(23):3034-3038.
13. Must A, Jacques PF, Dallal GE, Bajema CJ, Dietz WH. Long-term morbidity and mortality of overweight adolescents. A follow-up of the Harvard growth study of 1922 to 1935. *N Engl J Med*. 1992;327(19):1350-1355.
14. Bibbins-Domingo K, Coxson P, Pletcher MJ, Lightwood J, Goldman L. Adolescent overweight and future adult coronary heart disease. *N Engl J Med*. 2007;357(23):2371-2379.
15. Eiland LS, Luttrell PK. Use of statins for dyslipidemia in the pediatric population. *J Pediatr Pharmacol Ther*. 2010;15(3):160-172.
16. National Cholesterol Education Program (NCEP): highlights of the report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. *Pediatrics*. 1992;89(3):495-501.
17. Ritchie SK, Murphy EC, Ice C, et al. Universal versus targeted blood cholesterol screening among youth: The CARDIAC project. *Pediatrics*. 2010;126(2):260-265.
18. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. *Pediatrics*. 2011;128(suppl 5):S213-256.
19. Bertrais S, Balkau B, Charles MA, et al. Puberty-associated differences in total cholesterol and triglyceride levels according to sex in French children aged 10-13 years. *Ann Epidemiol*. 2000;10(5):316-323.
20. Kouda K, Nakamura H, Fan W, Takeuchi H. Negative relationships between growth in height and levels of cholesterol in puberty: a 3-year follow-up study. *Int J Epidemiol*. 2003;32(6):1105-1110.
21. Doran B, Guo Y, Xu J, et al. Prognostic value of fasting versus nonfasting low-density lipoprotein cholesterol levels on long-term mortality: insight from the National Health and Nutrition Examination Survey III (NHANES-III). *Circulation*. 2014;130(7):546-553.
22. Gooding HC, Rodday AM, Wong JB, et al. Application of pediatric and adult guidelines for treatment of lipid levels among US adolescents transitioning to young adulthood. *JAMA Pediatr*. 2015;169(6):569-574.

23. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. *Lancet*. 2005;366(9493):1267-1278.
24. Baigent C, Blackwell L, et al; Cholesterol Treatment Trialists C. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet*. 2010;376(9753):1670-1681.
25. Mills EJ, Wu P, Chong G, et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. *QJM*. 2011;104(2):109-124.
26. Tonelli M, Lloyd A, Clement F, et al. Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis. *CMAJ*. 2011;183(16):E1189-1202.
27. O'Gorman CS, Higgins MF, O'Neill MB. Systematic review and metaanalysis of statins for heterozygous familial hypercholesterolemia in children: evaluation of cholesterol changes and side effects. *Pediatr Cardiol*. 2009;30(4):482-489.
28. Vuorio A, Kuoppala J, Kovanen PT, et al. Statins for children with familial hypercholesterolemia. *Cochrane Database Syst Rev*. 2014;7:CD006401.
29. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. *Fundam Clin Pharmacol*. 2005;19(1):117-125.
30. Bilheimer DW, Grundy SM, Brown MS, Goldstein JL. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. *Proc Natl Acad Sci U S A*. 1983;80(13):4124-4128.
31. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. *Pharmacol Ther*. 1999;84(3):413-428.
32. Corsini A, Mazzotti M, Raiteri M, et al. Relationship between mevalonate pathway and arterial myocyte proliferation: *in vitro* studies with inhibitors of HMG-CoA reductase. *Atherosclerosis*. 1993;101(1):117-125.
33. Bernini F, Didoni G, Bonfadini G, Bellosta S, Fumagalli R. Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages. *Atherosclerosis*. 1993;104(1-2):19-26.
34. Clauss SB, Holmes KW, Hopkins P, et al. Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia. *Pediatrics*. 2005;116(3):682-688.
35. Stein EA, Illingworth DR, Kwiterovich PO Jr, et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. *JAMA*. 1999;281(2):137-144.
36. Lambert M, Lupien PJ, Gagne C, et al. Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group. *Pediatrics*. 1996;97(5):619-628.
37. de Jongh S, Ose L, Szamosi T, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. *Circulation*. 2002;106(17):2231-2237.
38. Ferreira WP, Bertolami MC, Santos SN, et al. One-month therapy with simvastatin restores endothelial function in hypercholesterolemic children and adolescents. *Pediatr Cardiol*. 2007;28(1):8-13.
39. Dirisamer A, Hachemian N, Bucek RA, et al. The effect of low-dose simvastatin in children with familial hypercholesterolemia: a 1-year observation. *Eur J Pediatr*. 2003;162(6):421-425.
40. de Jongh S, Lilien MR, op't Roodt J, et al. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. *J Am Coll Cardiol*. 2002;40(12):2117-2121.
41. Stefanutti C, Lucani G, Vivencio A, Di Giacomo S. Diet only and diet plus simvastatin in the treatment of heterozygous familial hypercholesterolemia in childhood. *Drugs Exp Clin Res*. 1999;25(1):23-28.
42. Garcia-de-la-Puente S, Arredondo-Garcia JL, Gutierrez-Castrellon P, et al. Efficacy of simvastatin in children with hyperlipidemia secondary to kidney disorders. *Pediatr Nephrol*. 2009;24(6):1205-1210.

43. Hedman M, Neuvonen PJ, Neuvonen M, Antikainen M. Pharmacokinetics and pharmacodynamics of pravastatin in children with familial hypercholesterolemia. *Clin Pharmacol Ther.* 2003;74(2):178-185.
44. Hedman M, Neuvonen PJ, Neuvonen M, et al. Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. *Clin Pharmacol Ther.* 2004;75(1):101-109.
45. Hedman M, Matikainen T, Fohr A, et al. Efficacy and safety of pravastatin in children and adolescents with heterozygous familial hypercholesterolemia: a prospective clinical follow-up study. *J Clin Endocrinol Metab.* 2005;90(4):1942-1952.
46. Hedman M, Antikainen M, Holmberg C, et al. Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes. *Br J Clin Pharmacol.* 2006;61(6):706-715.
47. Knipscheer HC, Boelen CC, Kastelein JJ, et al. Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia. *Pediatr Res.* 1996;39(5):867-871.
48. Wiegman A, Hutten BA, de Groot E, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. *JAMA.* 2004;292(3):331-337.
49. van der Graaf A, Nierman MC, Firth JC, et al. Efficacy and safety of fluvastatin in children and adolescents with heterozygous familial hypercholesterolaemia. *Acta Paediatr.* 2006;95(11):1461-1466.
50. McCrindle BW, Ose L, Marais AD. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. *J Pediatr.* 2003;143(1):74-80.
51. Gandelman K, Glue P, Laskey R, et al. An eight-week trial investigating the efficacy and tolerability of atorvastatin for children and adolescents with heterozygous familial hypercholesterolemia. *Pediatr Cardiol.* 2011;32(4):433-441.
52. Argent E, Kainer G, Aitken M, et al. Atorvastatin treatment for hyperlipidemia in pediatric renal transplant recipients. *Pediatr Transplant.* 2003;7(1):38-42.
53. Avis HJ, Hutten BA, Gagne C, et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. *J Am Coll Cardiol.* 2010;55(11):1121-1126.
54. Marais AD, Raal FJ, Stein EA, et al. A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolemia. *Atherosclerosis.* 2008;197(1):400-406.
55. Braamskamp MJ, Stefanutti C, Langslet G, et al. Efficacy and safety of pitavastatin in children and adolescents at high future cardiovascular risk. *J Pediatr.* 2015;167(2):338-343.
56. Duggan DE, Chen IW, Bayne WF, et al. The physiological disposition of lovastatin. *Drug Metab Dispos.* 1989;17(2):166-173.
57. Vickers S, Duncan CA, Chen IW, Rosegay A, Duggan DE. Metabolic disposition studies on simvastatin, a cholesterol-lowering pro-drug. *Drug Metab Dispos.* 1990;18(2):138-145.
58. McTaggart F, Buckett L, Davidson R, et al. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. *Am J Cardiol.* 2001;87(5A):28B-32B.
59. Kajinami K, Mabuchi H, Saito Y. NK-104: a novel synthetic HMG-CoA reductase inhibitor. *Expert Opin Investig Drugs.* 2000;9(11):2653-2661.
60. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. *Pharmacol Ther.* 2006;112(1):71-105.
61. Serajuddin AT, Ranadive SA, Mahoney EM. Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. *J Pharm Sci.* 1991;80(9):830-834.
62. Everett DW, Chando TJ, Didonato GC, et al. Biotransformation of pravastatin sodium in humans. *Drug Metab Dispos.* 1991;19(4):740-748.

63. Triscari J, O'Donnell D, Zinny M, Pan HY. Gastrointestinal absorption of pravastatin in healthy subjects. *J Clin Pharmacol*. 1995;35(2):142-144.
64. Ito MK. Effects of extensive and poor gastrointestinal metabolism on the pharmacodynamics of pravastatin. *J Clin Pharmacol*. 1998;38(4):331-336.
65. Singhvi SM, Pan HY, Morrison RA, Willard DA. Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. *Br J Clin Pharmacol*. 1990;29(2):239-243.
66. Nozawa T, Imai K, Nezu J, et al. Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. *J Pharmacol Exp Ther*. 2004;308(2):438-445.
67. Kobayashi D, Nozawa T, Imai K, et al. Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. *J Pharmacol Exp Ther*. 2003;306(2):703-708.
68. Shirasaka Y, Suzuki K, Nakanishi T, Tamai I. Intestinal absorption of HMG-CoA reductase inhibitor pravastatin mediated by organic anion transporting polypeptide. *Pharm Res*. 2010;27(10):2141-2149.
69. Kivisto KT, Grisk O, Hofmann U, et al. Disposition of oral and intravenous pravastatin in MRP2-deficient TR- rats. *Drug Metab Dispos*. 2005;33(11):1593-1596.
70. Kivisto KT, Niemi M. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. *Pharm Res*. 2007;24(2):239-247.
71. Yamazaki M, Akiyama S, Ni'inuma K, et al. Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter. *Drug Metab Dispos*. 1997;25(10):1123-1129.
72. Niemi M, Arnold KA, Backman JT, et al. Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics. *Pharmacogenet Genomics*. 2006;16(11):801-808.
73. Varma MV, Rotter CJ, Chupka J, et al. pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1. *Mol Pharm*. 2011;8(4):1303-1313.
74. Huang L, Wang Y, Grimm S. ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. *Drug Metab Dispos*. 2006;34(5):738-742.
75. Keskitalo JE, Zolk O, Fromm MF, et al. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. *Clin Pharmacol Ther*. 2009;86(2):197-203.
76. Zhang W, Yu BN, He YJ, et al. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. *Clin Chim Acta*. 2006;373(1-2):99-103.
77. Shirasaka Y, Suzuki K, Nakanishi T, Tamai I. Differential effect of grapefruit juice on intestinal absorption of statins due to inhibition of organic anion transporting polypeptide and/or P-glycoprotein. *J Pharm Sci*. 2011;100(9):3843-3853.
78. Shirasaka Y, Suzuki K, Shichiri M, et al. Intestinal absorption of HMG-CoA reductase inhibitor pitavastatin mediated by organic anion transporting polypeptide and P-glycoprotein/multidrug resistance 1. *Drug Metab Pharmacokinet*. 2011;26(2):171-179.
79. Smith HT, Jokubaitis LA, Troendle AJ, et al. Pharmacokinetics of fluvastatin and specific drug interactions. *Am J Hypertens*. 1993;6(11 Pt 2):375S-382S.
80. Pan HY, DeVault AR, Brescia D, et al. Effect of food on pravastatin pharmacokinetics and pharmacodynamics. *Int J Clin Pharmacol Ther Toxicol*. 1993;31(6):291-294.
81. Li Y, Jiang X, Lan K, et al. Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. *Clin Ther*. 2007;29(10):2194-2203.
82. Radulovic LL, Cilla DD, Posvar EL, et al. Effect of food on the bioavailability of atorvastatin, an HMG-CoA reductase inhibitor. *J Clin Pharmacol*. 1995;35(10):990-994.

83. Shang D, Deng S, Yao Z, et al. The effect of food on the pharmacokinetic properties and bioequivalence of two formulations of pitavastatin calcium in healthy Chinese male subjects. *Xenobiotica*. 2015:1-6.
84. Lovastatin Mevacor(R) [package insert]. Merck & Co., Inc., Kenilworth, New Jersey: 1987. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019643s0881-bl.pdf. November 10, 2015.
85. Simvastatin. Zocor(R) [package insert]. Merck & Co., Inc. Kenilworth, New Jersey; 1991. 2015.
86. Triscari J, Rossi L, Pan HY. Chronokinetics of pravastatin administered in the PM compared with AM dosing. *Am J Ther*. 1995;2(4):265-268.
87. Cilla DD Jr, Gibson DM, Whitfield LR, Sedman AJ. Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening. *J Clin Pharmacol*. 1996;36(7):604-609.
88. Fauler G, Abletshauer C, Erwa W, et al. Time-of-intake (morning versus evening) of extended-release fluvastatin in hyperlipemic patients is without influence on the pharmacodynamics (mevalonic acid excretion) and pharmacokinetics. *Int J Clin Pharmacol Ther*. 2007;45(6):328-334.
89. Martin PD, Mitchell PD, Schneck DW. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. *Br J Clin Pharmacol*. 2002;54(5):472-477.
90. Goo RH, Moore JG, Greenberg E, Alazraki NP. Circadian variation in gastric emptying of meals in humans. *Gastroenterology*. 1987;93(3):515-518.
91. Pappu AS, Illingworth DR. Diurnal variations in the plasma concentrations of mevalonic acid in patients with abetalipoproteinemia. *Eur J Clin Invest*. 1994;24(10):698-702.
92. Jones PJ, Schoeller DA. Evidence for diurnal periodicity in human cholesterol synthesis. *J Lipid Res*. 1990;31(4):667-673.
93. Tse FL, Jaffe JM, Troendle A. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. *J Clin Pharmacol*. 1992;32(7):630-638.
94. Pan HY, DeVault AR, Wang-Iverson D, et al. Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. *J Clin Pharmacol*. 1990;30(12):1128-1135.
95. Lennernas H. Clinical pharmacokinetics of atorvastatin. *Clin Pharmacokinet*. 2003;42(13):1141-1160.
96. Martin PD, Warwick MJ, Dane AL, et al. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. *Clin Ther*. 2003;25(10):2553-2563.
97. Voora D, Shah SH, Spasojevic I, et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. *J Am Coll Cardiol*. 2009;54(17):1609-1616.
98. Neuvonen PJ, Backman JT, Niemi M. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. *Clin Pharmacokinet*. 2008;47(7):463-474.
99. Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. *Pharmacol Rev*. 2011;63(1):157-181.
100. Wagner J, Leeder JS. Pediatric pharmacogenomics: a systematic assessment of ontogeny and genetic variation to guide the design of statin studies in children. *Pediatr Clin North Am*. 2012;59(5):1017-1037.
101. Fujino H, Saito T, Ogawa S, Kojima J. Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. *J Pharm Pharmacol*. 2005;57(10):1305-1311.
102. Hirano M, Maeda K, Shitara Y, Sugiyama Y. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. *J Pharmacol Exp Ther*. 2004;311(1):139-146.
103. Ho RH, Tirona RG, Leake BF, et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. *Gastroenterology*. 2006;130(6):1793-1806.
104. Kitamura S, Maeda K, Wang Y, Sugiyama Y. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. *Drug Metab Dispos*. 2008;36(10):2014-2023.

105. Kopplov K, Letschert K, Konig J, et al. Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. *Mol Pharmacol*. 2005;68(4):1031-1038.
106. Niemi M, Pasanen MK, Neuvonen PJ. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. *Clin Pharmacol Ther*. 2006;80(4):356-366.
107. Deng JW, Song IS, Shin HJ, et al. The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. *Pharmacogenet Genomics*. 2008;18(5):424-433.
108. Kameyama Y, Yamashita K, Kobayashi K, et al. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. *Pharmacogenet Genomics*. 2005;15(7):513-522.
109. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. *Pharmacogenet Genomics*. 2006;16(12):873-879.
110. Hsiang B, Zhu Y, Wang Z, et al. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. *J Biol Chem*. 1999;274(52):37161-37168.
111. Chen C, Mireles RJ, Campbell SD, et al. Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. *Drug Metab Dispos*. 2005;33(4):537-546.
112. Tirona RG, Leake BF, Wolkoff AW, Kim RB. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. *J Pharmacol Exp Ther*. 2003;304(1):223-228.
113. Vavricka SR, Van Montfoort J, Ha HR, et al. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. *Hepatology*. 2002;36(1):164-172.
114. Lau YY, Huang Y, Frassetto L, Benet LZ. effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. *Clin Pharmacol Ther*. 2007;81(2):194-204.
115. Asberg A, Hartmann A, Fjeldsa E, et al. Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. *Am J Transplant*. 2001;1(4):382-386.
116. Hermann M, Asberg A, Christensen H, et al. Substantially elevated levels of atorvastatin and metabolites in cyclosporine-treated renal transplant recipients. *Clin Pharmacol Ther*. 2004;76(4):388-391.
117. Lemahieu WP, Hermann M, Asberg A, et al. Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus. *Am J Transplant*. 2005;5(9):2236-2243.
118. Park JW, Siekmeier R, Lattke P, et al. Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. *J Cardiovasc Pharmacol Ther*. 2001;6(4):351-361.
119. Olbricht C, Wanner C, Eisenhauer T, et al. Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses. *Clin Pharmacol Ther*. 1997;62(3):311-321.
120. Regazzi MB, Iacona I, Campana C, et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. *Transplant Proc*. 1993;25(4):2732-2734.
121. Simonson SG, Raza A, Martin PD, et al. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. *Clin Pharmacol Ther*. 2004;76(2):167-177.
122. Arnadottir M, Eriksson LO, Thysell H, Karkas JD. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without cyclosporin. *Nephron*. 1993;65(3):410-413.
123. Ichimaru N, Takahara S, Kokado Y, et al. Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. *Atherosclerosis*. 2001;158(2):417-423.

124. Martin PD, Warwick MJ, Dane AL, et al. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. *Clin Ther*. 2003;25(11):2822-2835.
125. Fujino H, Yamada I, Shimada S, et al. Metabolic fate of pitavastatin (NK-104), a new inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase. Effects on drug-metabolizing systems in rats and humans. *Arzneimittelforschung*. 2002;52(10):745-753.
126. Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. *Clin Pharmacol Ther*. 1996;60(1):54-61.
127. Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. *Clin Pharmacol Ther*. 1998;63(3):332-341.
128. Kivisto KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. *Br J Clin Pharmacol*. 1998;46(1):49-53.
129. Backman JT, Luurila H, Neuvonen M, Neuvonen PJ. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. *Clin Pharmacol Ther*. 2005;78(2):154-167.
130. Kyrklund C, Backman JT, Kivisto KT, et al. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. *Clin Pharmacol Ther*. 2001;69(5):340-345.
131. Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. *Clin Pharmacol Ther*. 2003;73(6):538-544.
132. Schneck DW, Birmingham BK, Zalikowski JA, et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. *Clin Pharmacol Ther*. 2004;75(5):455-463.
133. Backman JT, Kyrklund C, Kivisto KT, et al. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. *Clin Pharmacol Ther*. 2000;68(2):122-129.
134. Hagenbuch B, Meier PJ. Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. *Pflugers Arch*. 2004;447(5):653-665.
135. Ogawa K, Hasegawa S, Udaka Y, et al. Individual difference in the pharmacokinetics of a drug, pravastatin, in healthy subjects. *J Clin Pharmacol*. 2003;43(11):1268-1273.
136. Nishizato Y, Ieiri I, Suzuk iH, et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. *Clin. Pharmacol. Ther*. 2003;73:554-565.
137. Niemi M, Schaeffeler E, Lang T, et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). *Pharmacogenetics*. 2004;14(7):429-440.
138. He YJ, Zhang W, Chen Y, et al. Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. *Clin Chim Acta*. 2009;405(1-2):49-52.
139. SEARCH, Collaborative, Group, et al. SLCO1B1 variants and statin-induced myopathy—a genomewide study. *N Engl J Med*. 2008;359:789-799.
140. Pan HY, Waclawski AP, Funke PT, Whigan D. Pharmacokinetics of pravastatin in elderly versus young men and women. *Ann Pharmacother*. 1993;27(9):1029-1033.
141. Tse FL, Nickerson DF, Yardley WS. Binding of fluvastatin to blood cells and plasma proteins. *J Pharm Sci*. 1993;82(9):942-947.
142. Botti RE, Triscari J, Pan HY, Zayat J. Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects. *Clin Neuropharmacol*. 1991;14(3):256-261.
143. Johnson-Anuna LN, Eckert GP, Keller JH, et al. Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex. *J Pharmacol Exp Ther*. 2005;312(2):786-793.
144. Pierno S, De Luca A, Tricarico D, et al. Potential risk of myopathy by HMG-CoA reductase inhibitors: a comparison of pravastatin and simvastatin effects on membrane electrical properties of rat skeletal muscle fibers. *J Pharmacol Exp Ther*. 1995;275(3):1490-1496.
145. Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study. *Cardiovasc Drugs Ther*. 2005;19(6):403-414.

146. Masters BA, Palmoski MJ, Flint OP, et al. *In vitro* myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. *Toxicol Appl Pharmacol.* 1995;131(1):163-174.
147. Nakahara K, Kuriyama M, Sonoda Y, et al. Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological, and biochemical study. *Toxicol Appl Pharmacol.* 1998;152(1):99-106.
148. Gadbut AP, Caruso AP, Galper JB. Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin. *J Mol Cell Cardiol.* 1995;27(10):2397-2402.
149. Reijneveld JC, Koot RW, Bredman JJ, et al. Differential effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on the development of myopathy in young rats. *Pediatr Res.* 1996;39(6):1028-1035.
150. Prueksaritanont T, Ma B, Yu N. The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. *Br J Clin Pharmacol.* 2003;56(1):120-124.
151. Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. *Am J Cardiol.* 2004;94(9):1140-1146.
152. Prueksaritanont T, Gorham LM, Ma B, et al. *In vitro* metabolism of simvastatin in humans: Identification of metabolizing enzymes and effect of the drug on hepatic P450s. *Drug Metab Dispos.* 1997;25(10):1191-1199.
153. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. *Clin Pharmacol Ther.* 2006;80(6):565-581.
154. Scripture CD, Pieper JA. Clinical pharmacokinetics of fluvastatin. *Clin Pharmacokinet.* 2001;40(4):263-281.
155. Transon C, Leemann T, Dayer P. *In vitro* comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. *Eur J Clin Pharmacol.* 1996;50(3):209-215.
156. Transon C, Leemann T, Vogt N, Dayer P. *In vivo* inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. *Clin Pharmacol Ther.* 1995;58(4):412-417.
157. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. *Adv Drug Deliv Rev.* 2002;54(10):1271-1294.
158. Wang D, Guo Y, Wrighton SA, et al. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. *Pharmacogenomics J.* 2010;11(4):274-286.
159. Elens L, Becker ML, Haufroid V, et al. Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam study. *Pharmacogenet Genomics.* 2011 21(12):861-866.
160. Kirchheiner J, Kudlicz D, Meisel C, et al. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. *Clin Pharmacol Ther.* 2003;74(2):186-194.
161. Fujino H, Yamada I, Shimada S, Yoneda M, Kojima J. Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization. *Xenobiotica.* 2003;33(1):27-41.
162. Prueksaritanont T, Subramanian R, Fang X, et al. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. *Drug Metab Dispos.* 2002;30(5):505-512.
163. Fujino H, Saito T, Tsunenari Y, Kojima J, Sakaeda T. Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors. *Xenobiotica.* 2004;34(11-12):961-971.
164. Riedmaier S, Klein K, Hofmann U, et al. UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization *in vitro* and *in vivo*. *Clin Pharmacol Ther.* 2010;87(1):65-73.
165. Cho SK, Oh ES, Park K, et al. The UGT1A3*2 polymorphism affects atorvastatin lactonization and lipid-lowering effect in healthy volunteers. *Pharmacogenet Genomics.* 2012;22(8):598-605.
166. Leschziner GD, Andrew T, Pirmohamed M, Johnson MR. ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. *Pharmacogenomics J.* 2007;7(3):154-179.

167. Keskitalo JE, Kurkinen KJ, Neuvonen M, et al. No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin. *Br J Clin Pharmacol*. 2009;68(2):207-213.
168. Keskitalo JE, Kurkinen KJ, Neuvonen PJ, Niemi M. ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. *Clin Pharmacol Ther*. 2008;84(4):457-461.
169. Imai Y, Nakane M, Kage K, et al. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. *Mol Cancer Ther*. 2002;1(8):611-616.
170. Keskitalo JE, Pasanen MK, Neuvonen PJ, Niemi M. Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. *Pharmacogenomics*. 2009;10(10):1617-1624.
171. Hirano M, Maeda K, Hayashi H, et al. Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin. *J Pharmacol Exp Ther*. 2005;314(2):876-882.
172. Stern RH, Yang BB, Horton M, et al. Renal dysfunction does not alter the pharmacokinetics or LDL-cholesterol reduction of atorvastatin. *J Clin Pharmacol*. 1997;37(9):816-819.
173. Halstenson CE, Triscari J, DeVault A, et al. Single-dose pharmacokinetics of pravastatin and metabolites in patients with renal impairment. *J Clin Pharmacol*. 1992;32(2):124-132.
174. Hasegawa M, Kusuhara H, Sugiyama D, et al. Functional involvement of rat organic anion transporter 3 (rOat3; Slc22a8) in the renal uptake of organic anions. *J Pharmacol Exp Ther*. 2002;300(3):746-753.
175. Takeda M, Noshiro R, Onozato ML, et al. Evidence for a role of human organic anion transporters in the muscular side effects of HMG-CoA reductase inhibitors. *Eur J Pharmacol*. 2004;483(2-3):133-138.
176. Nakagomi-Hagihara R, Nakai D, Tokui T. Inhibition of human organic anion transporter 3 mediated pravastatin transport by gemfibrozil and the metabolites in humans. *Xenobiotica*. 2007;37(4):416-426.
177. Hebbel RP. Special issue of Microcirculation: examination of the vascular pathobiology of sickle cell anemia. Foreword. *Microcirculation*. 2004;11(2):99-100.
178. Hoppe C, Kuypers F, Larkin S, et al. A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction. *Br J Haematol*. 2011 153(5):655-663.
179. Mahle WT, Vincent RN, Berg AM, Kanter KR. Pravastatin therapy is associated with reduction in coronary allograft vasculopathy in pediatric heart transplantation. *J Heart Lung Transplant*. 2005;24:63066.
180. Singh TP, Naftel DC, Webber S, et al. Hyperlipidemia in children after heart transplantation. *J Heart Lung Transplant*. 2006;25:1199-1205.
181. Azuma RW, Suzuki J, Ogawa M, et al. HMG-CoA reductase inhibitor attenuates experimental autoimmune myocarditis through inhibition of T cell activation. *Cardiovasc Res*. 2004;64(3):412-420.
182. Tang Q, Huang J, Qian H, et al. Antiarrhythmic effect of atorvastatin on autoimmune myocarditis is mediated by improving myocardial repolarization. *Life Sci*. 2007;80(7):601-608.
183. Zembala M, Wojnicz R, Zakliczynski M, et al. Cellular adhesion molecules changes in myocardium during first year post heart transplant. *Ann Transplant*. 1997;2(2):16-19.
184. Stojanovic I, Vrtovec B, Radovancevic B, et al. Survival, graft atherosclerosis, and rejection incidence in heart transplant recipients treated with statins: 5-year follow-up. *J Heart Lung Transplant*. 2005;24(9):1235-1238.
185. Wenke K, Meiser B, Thiery J, Reichart B. Impact of simvastatin therapy after heart transplantation an 11-year prospective evaluation. *Herz*. 2005;30(5):431-432.
186. Fildes JE, Shaw SM, Mitsidou A, et al. HMG-CoA reductase inhibitors deplete circulating classical and non-classical monocytes following human heart transplantation. *Transpl Immunol*. 2008;19(2):152-157.
187. Grigioni F, Carigi S, Potena L, et al. Long-term safety and effectiveness of statins for heart transplant recipients in routine clinical practice. *Transplant Proc*. 2006;38(5):1507-1510.

188. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. *N Engl J Med*. 1995;333(10):621-627.
189. Mahle WT, Vincent RN, Berg AM, Kanter KR. Pravastatin therapy is associated with reduction in coronary allograft vasculopathy in pediatric heart transplantation. *J Heart Lung Transplant*. 2005;24(1):63-66.
190. Singh TP, Naftel DC, Webber S, et al. Hyperlipidemia in children after heart transplantation. *J Heart Lung Transplant*. 2006;25(10):1199-1205.
191. Frohlich GM, Rufibach K, Enseleit F, et al. Statins and the risk of cancer after heart transplantation. *Circulation*. 2012;126(4):440-447.
192. Murtola TJ, Tammela TL, Maattanen L, et al. Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial. *Int J Cancer*. 2010;127(7):1650-1659.
193. Cho SJ, Kim JS, Kim JM, et al. Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice. *Int J Cancer*. 2008;123(4):951-957.
194. Spampanato C, De Maria S, Sarnataro M, et al. Simvastatin inhibits cancer cell growth by inducing apoptosis correlated to activation of Bax and down-regulation of BCL-2 gene expression. *Int J Oncol*. 2012;40(4):935-941.
195. Denoyelle C, Vasse M, Korner M, et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an *in vitro* study. *Carcinogenesis*. 2001;22(8):1139-1148.
196. Sanguankeo A, Upala S, Cheungpasitporn W, et al. Effects of statins on renal outcome in chronic kidney disease patients: a systematic review and meta-analysis. *PLoS One*. 2015;10(7):e0132970.
197. Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction? *Expert Opin Pharmacother*. 2015;16(10):1449-1461.
198. Yan YL, Qiu B, Wang J, et al. High-intensity statin therapy in patients with chronic kidney disease: a systematic review and meta-analysis. *BMJ Open*. 2015;5(5):e006886.
199. Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation *in vitro* and in rodents by statins. *Science*. 1999;286(5446):1946-1949.
200. Park YS, David AE, Park KM, et al. Controlled release of simvastatin from in situ forming hydrogel triggers bone formation in MC3T3-E1 cells. *AAPS J*. 2013;15(2):367-376.
201. Majima T, Shimatsu A, Komatsu Y, et al. Short-term effects of pitavastatin on biochemical markers of bone turnover in patients with hypercholesterolemia. *Intern Med*. 2007;46(24):1967-1973.
202. Safaei H, Janghorbani M, Aminorroaya A, Amini M. Lovastatin effects on bone mineral density in postmenopausal women with type 2 diabetes mellitus. *Acta Diabetol*. 2007;44(2):76-82.
203. Perez-Castrillon JL, Vega G, Abad L, et al. Effect of the TNFalpha-308 G/A polymorphism on the changes produced by atorvastatin in bone mineral density in patients with acute coronary syndrome. *Ann Nutr Metab*. 2008;53(2):117-121.
204. Kanazawa I, Yamaguchi T, Yamauchi M, Sugimoto T. Rosuvastatin increased serum osteocalcin levels independent of its serum cholesterol-lowering effect in patients with type 2 diabetes and hypercholesterolemia. *Intern Med*. 2009;48(21):1869-1873.
205. Baker JV, Huppler Hullsiek K, Prosser R, et al. Angiotensin converting enzyme inhibitor and HMG-CoA reductase inhibitor as adjunct treatment for persons with HIV infection: a feasibility randomized trial. *PLoS One*. 2012;7(10):e46894.
206. Boccarda F, Simon T, Lacombe K, et al. Influence of pravastatin on carotid artery structure and function in dyslipidemic HIV-infected patients receiving antiretroviral therapy. *AIDS*. 2006;20(18):2395-2398.
207. Hurlimann D, Chenevard R, Ruschitzka F, et al. Effects of statins on endothelial function and lipid profile in HIV infected persons receiving protease inhibitor-containing anti-retroviral combination therapy: a randomised double blind crossover trial. *Heart*. 2006;92(1):110-112.

208. Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. *Lancet*. 2009;373(9670):1175-1182.
209. Calza L, Vanino E, Salvadori C, et al. Tenofovir/emtricitabine/efavirenz plus rosuvastatin decrease serum levels of inflammatory markers more than antiretroviral drugs alone in antiretroviral therapy-naive HIV-infected patients. *HIV Clin Trials*. 2014;15(1):1-13.
210. Funderburg NT, Jiang Y, Debanne SM, et al. Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy. *Clin Infect Dis*. 2014;58(4):588-595.
211. Rasmussen LD, Kronborg G, Larsen CS, et al. Statin therapy and mortality in HIV-infected individuals; a Danish nationwide population-based cohort study. *PLoS One*. 2013;8(3):e52828.
212. Amuro H, Ito T, Miyamoto R, et al. Statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, function as inhibitors of cellular and molecular components involved in type I interferon production. *Arthritis Rheum*. 2010;62(7):2073-2085.
213. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. *Nat Rev Drug Discov*. 2005;4(12):977-987.
214. Mira E, Manes S. Immunomodulatory and anti-inflammatory activities of statins. *Endocr Metab Immune Disord Drug Targets*. 2009;9(3):237-247.
215. Yasuda H, Yuen PS, Hu X, et al. Simvastatin improves sepsis-induced mortality and acute kidney injury via renal vascular effects. *Kidney Int*. 2006;69(9):1535-1542.
216. Tleyjeh IM, Kashour T, Hakim FA, et al. Statins for the prevention and treatment of infections: a systematic review and meta-analysis. *Arch Intern Med*. 2009;169(18):1658-1667.
217. Fedson DS. Confronting an influenza pandemic with inexpensive generic agents: can it be done? *Lancet Infect Dis*. 2008;8(9):571-576.
218. Thomsen RW, Riis A, Kornum JB, et al. Pre-admission use of statins and outcomes after hospitalization with pneumonia: population-based cohort study of 29,900 patients. *Arch Intern Med*. 2008;168(19):2081-2087.
219. Schanberg LE, Sandborg C, Barnhart HX, et al. Use of atorvastatin in systemic lupus erythematosus in children and adolescents. *Arthritis Rheum*. 2012;64(1):285-296.
220. Mok CC, Wong CK, To CH, et al. Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: a randomized, double-blind, placebo-controlled trial. *Arthritis Care Res (Hoboken)*. 2011;63(6):875-883.
221. Ferreira GA, Navarro TP, Telles RW, et al. Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. *Rheumatology (Oxford)*. 2007;46(10):1560-1565.
222. Ferreira GA, Teixeira AL, Sato EI. Atorvastatin therapy reduces interferon-regulated chemokine CXCL9 plasma levels in patients with systemic lupus erythematosus. *Lupus*. 2010;19(8):927-934.
223. Sathyapalan T, Kilpatrick ES, Coady AM, Atkin SL. The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. *J Clin Endocrinol Metab*. 2009;94(1):103-108.
224. Banaszewska B, Pawelczyk L, Spaczynski RZ, et al. Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. *J Clin Endocrinol Metab*. 2007;92(2):456-461.
225. Gao L, Zhao FL, Li SC. Statin is a reasonable treatment option for patients with polycystic ovary syndrome: a meta-analysis of randomized controlled trials. *Exp Clin Endocrinol Diabetes*. 2012;120(6):367-375.
226. Lv S, Liu Y, Zou Z, et al. The impact of statins therapy on disease activity and inflammatory factor in patients with rheumatoid arthritis: a meta-analysis. *Clin Exp Rheumatol*. 2015;33(1):69-76.
227. Schoenfeld SR, Lu L, Rai SK, et al. Statin use and mortality in rheumatoid arthritis: a general population-based cohort study. *Ann Rheum Dis*. 2016;75(7):1315-1320.

228. Xing B, Yin YF, Zhao LD, et al. Effect of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor on disease activity in patients with rheumatoid arthritis: a meta-analysis. *Medicine (Baltimore)*. 2015;94(8):e572.
229. Pereira MC, Cardoso PR, Da Rocha LF Jr, et al. Simvastatin inhibits cytokines in a dose response in patients with rheumatoid arthritis. *Inflamm Res*. 2014;63(4):309-315.
230. Lin H, Xiao Y, Chen G, et al. HMG-CoA reductase inhibitor simvastatin suppresses Toll-like receptor 2 ligand-induced activation of nuclear factor kappa B by preventing RhoA activation in monocytes from rheumatoid arthritis patients. *Rheumatol Int*. 2011;31(11):1451-1458.
231. McCarey DW, McInnes IB, Madhok R, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. *Lancet*. 2004;363(9426):2015-2021.
232. Dolkart O, Liron T, Chechik O, et al. Statins enhance rotator cuff healing by stimulating the COX2/PGE2/EP4 pathway: an *in vivo* and *in vitro* study. *Am J Sports Med*. 2014;42(12):2869-2876.
233. Lin TT, Lin CH, Chang CL, et al. The effect of diabetes, hyperlipidemia, and statins on the development of rotator cuff disease: a nationwide, 11-year, longitudinal, population-based follow-up study. *Am J Sports Med*. 2015;43(9):2126-2132.
234. Joukhadar C, Klein N, Prinz M, et al. Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia. *Thromb Haemost*. 2001;85(1):47-51.
235. Nomura S, Shouzu A, Omoto S, et al. Effects of losartan and simvastatin on monocyte-derived microparticles in hypertensive patients with and without type 2 diabetes mellitus. *Clin Appl Thromb Hemost*. 2004;10(2):133-141.
236. Wagner AH, Kohler T, Ruckschloss U, et al. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. *Arterioscler Thromb Vasc Biol*. 2000;20(1):61-69.
237. Couture P, Brun LD, Szots F, et al. Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia. *Arterioscler Thromb Vasc Biol*. 1998;18(6):1007-1012.
238. Vohl MC, Szots F, Lelievre M, et al. Influence of LDL receptor gene mutation and apo E polymorphism on lipoprotein response to simvastatin treatment among adolescents with heterozygous familial hypercholesterolemia. *Atherosclerosis*. 2002;160(2):361-368.
239. Koeijvoets KC, Rodenburg J, Hutten BA, et al. Low-density lipoprotein receptor genotype and response to pravastatin in children with familial hypercholesterolemia: sub-study of an intima-media thickness trial. *Circulation*. 15 2005;112(20):3168-3173.
240. Krauss RM, Mangravite LM, Smith JD, et al. Variation in the 3-hydroxy-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. *Circulation*. 2008;117(12):1537-1544.
241. Medina MW, Gao F, Ruan W, et al. Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin. *Circulation*. 2008;118(4):355-362.